TY - JOUR
T1 - Pneumotoxicity associated with immune checkpoint inhibitor therapies
AU - Shannon, Vickie R.
N1 - Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Purpose of review Immune checkpoint inhibitor therapies represent a new paradigm in cancer therapeutics, in which the targets are not the cancer cells, but the body's own immune system. Harnessing the immune system to better fight cancer has generated a unique spectrum of immune-related adverse events (IrAEs) that effect virtually every major organ system. Although lung involvement is less common than other forms of IrAEs, its consequences are potentially lethal. This review focuses on the evolving spectrum of lung toxicities associated with the two major classes of immune checkpoint inhibitor therapies, cytotoxic T-cell ligand-4, and programed cell death-1 (PDL-1). Recent findings Lung injury was not reported in the earliest clinical trials of immune checkpoint inhibitors. More recent studies, however, have described unique radiographic and clinical toxicity profiles that differ significantly from lung injury patterns associated with conventional cytotoxic therapies. The pathophysiologic mechanisms of immune-related lung injury, its radiographic and clinical disease spectrum, associated risk factors, and optimal treatment strategies remain poorly understood. Summary Adverse immune-mediated lung events are increasingly recognized as unique and potentially life-Threatening sequelae of checkpoint inhibitor therapies. Early recognition of symptoms and radiographic abnormalities is essential to proper management and successful outcome.
AB - Purpose of review Immune checkpoint inhibitor therapies represent a new paradigm in cancer therapeutics, in which the targets are not the cancer cells, but the body's own immune system. Harnessing the immune system to better fight cancer has generated a unique spectrum of immune-related adverse events (IrAEs) that effect virtually every major organ system. Although lung involvement is less common than other forms of IrAEs, its consequences are potentially lethal. This review focuses on the evolving spectrum of lung toxicities associated with the two major classes of immune checkpoint inhibitor therapies, cytotoxic T-cell ligand-4, and programed cell death-1 (PDL-1). Recent findings Lung injury was not reported in the earliest clinical trials of immune checkpoint inhibitors. More recent studies, however, have described unique radiographic and clinical toxicity profiles that differ significantly from lung injury patterns associated with conventional cytotoxic therapies. The pathophysiologic mechanisms of immune-related lung injury, its radiographic and clinical disease spectrum, associated risk factors, and optimal treatment strategies remain poorly understood. Summary Adverse immune-mediated lung events are increasingly recognized as unique and potentially life-Threatening sequelae of checkpoint inhibitor therapies. Early recognition of symptoms and radiographic abnormalities is essential to proper management and successful outcome.
KW - adverse events
KW - immune checkpoint inhibitor
KW - pneumotoxicity
UR - http://www.scopus.com/inward/record.url?scp=85017472960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017472960&partnerID=8YFLogxK
U2 - 10.1097/MCP.0000000000000382
DO - 10.1097/MCP.0000000000000382
M3 - Review article
C2 - 28403039
AN - SCOPUS:85017472960
SN - 1070-5287
VL - 23
SP - 305
EP - 316
JO - Current opinion in pulmonary medicine
JF - Current opinion in pulmonary medicine
IS - 4
ER -